A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 111
Summary
- Conditions
- Gastric Carcinoma
- Bladder Cancer
- Cervical Cancer
- Classical Hodgkin Lymphoma
- Cutaneous Melanoma
- Diffuse Large B Cell Lymphoma
- Gastroesophageal Junction Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Non -Small Cell Lung Cancer
- Triple -Negative Breast Cancer
- Ovarian Cancer
- Peripheral T Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04254107
- Collaborators
- Not Provided
- Investigators
- Study Director: Andres Forero-Torres, MD Seagen Inc.
Get Well Soon